Infectious Diseases Research

Below are current clinical trials.

272 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. Benznidazole for treatment of Chagas Disease (American trypanosomiasis)

   Scottsdale/Phoenix, Ariz.

   The objective of the treatment program described here is to make benznidazole available in the United States on a compassionate-use basis for treatment of T. cruzi infection—specifically, for patients who have acute or congenital infection, reactivated infection, or chronic infection (without advanced cardiac disease)—and for prophylaxis of infection, when indicated in the setting of proven exposure. Benznidazole will be provided for individual patients who meet the eligibility criteria, on request of the treating physician, after consultation with CDC staff.

2. A Study of Nervous System Involvement of Coccidioidomycosis at Mayo Clinic Hospital in Arizona

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to gain a better understanding of the presentation, diagnostics, disease course and treatment variations, as well as the factors that may influence features of neuro-invasive Coccidioidomycosis. 

3. A Study of the Quantiferon CMV Blood Test to Predict the Risk of CMV Returning After Treatment of the Disease in Solid Organ Transplant Recipients

   Rochester, Minn.

   The overall aim of this study is to determine whether solid organ transplant recipients who develop immunity to cytomegalovirus (CMV) after an initial episode of CMV disease as measured by the QuantiFERON-CMV assay are at lower risk of CMV recurrence in the future.

4. A Study of the Prevalence of the Oropharyngeal Human Papillomavirus in Partners of Patients with Oropharyngeal Squamous Cell Carcinoma

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   We are doing this research study to find out if partners of subjects with oropharyngeal cancer are infected with human papillomavirus (HPV) in their mouth or throat. Human papillomavirus causes some types of oropharyngeal cancer. It is not known if sexual partners of patients are at higher risk of having oral or throat HPV infection. It is also unknown if certain sexual behaviors increase the risk of oral HPV infection

5. A Study Using VE303 to Prevent Recurrence of Clostridium Difficile Infection

   Rochester, Minn.

   The purpose of this study will evaluate the safety and effectiveness of VE303 for participants with recurrent Clostridium difficile infection (rCDI).

6. Testing of Real-Time Diagnostic Platform (HPView) for the Detection of High-risk HPV Strains in Urine

   Rochester, Minn.

   The purpose of this study is to test whether our developed real-time HPV detection platform (HPView) performs at a comparable level to the clinical gold-standard.

7. "Less Pain, Less Fuss, Right Now!" and "Make It Count!"- Efforts to Enhance Provider Recommendations for HPV Vaccination

   Rochester, Minn.

   We are testing this hypothesis through three phases for which we have developed three protocols. In this phase, with this protocol, we have two primary aims.

   • Aim 1: To assess acceptability and gather input on the design and content of an as-of-yet undistributed reminder-recall to parents of children 11-12 years of age due for an HPV dose that emphasized the pain-reducing measures and the nurse visits

   • Aim 2: To evaluate the process of distributing the reminder-recalls to parents of children 11-12 years of age due for an HPV dose that emphasized the pain-reducing measures and the nurse visits

8. Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

   Rochester, Minn.

   This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B. Hospitalized subjects with influenza A or B that have either a low oxygen level or a high respiratory rate will be eligible for study participation. This study will enroll adults, children and pregnant women.

9. Development of Potential COVID-19 Vaccine and Serological Assay

   Rochester, Minn.

   Our group has explored the use of genomic RNA/phage display libraries derived from primary human malignant melanoma cells as a means of identifying antibody detectable targets on cancer cells (cancer vaccines or antibody guided therapeutics).  In this approach, we isolate and affinity-column immobilize the IgG fraction from patient serum before and after immune therapy for melanoma, and expose the immobilized antibodies to bacteriophage expressing approximately 2x109 overlapping cDNA sequences of paired (same patient derived plasma and cancer cells) melanoma genomic RNA.  Phage, expressing melanoma cDNA express the proteins/peptides on their capsid are “recognized” by the immobilized antibodies are retained in the column, and subsequently eluted for DNA sequencing.  Comparison of the DNA profiles of the eluted phage using pre-immunotherapy and post-immunotherapy patient sera will reveal emergence of new antibodies (post-immunotherapy gain of antibodies) against proteins of potential interest for melanoma targeting.  In the current proposal, we hypothesize that reacting COVID serum from patients that have recovered from COVID infection and compare to non-infected self-serum (if available) and control healthy volunteer serum (available in our lab) may identify protein targets that have developed as a result of the COVID infection and could be useful in the development of a COVID vaccine as well as a serologic test for anti-COVID immunity. 

10. A Study for the Use of Hepatitis C Virus Seropositive Donors into Hepatitis C Seronegative Liver Transplant Recipients

    Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The purpose of this study is to utilize liver allografts from HCV seropositive donors into 10 HCV seronegative recipients.